The estimated Net Worth of James J Loughlin is at least $567 mil dollars as of 13 June 2019. James Loughlin owns over 3,225 units of PDS Biotechnology stock worth over $129,769 and over the last 18 years James sold PDSB stock worth over $437,304.
James has made over 53 trades of the PDS Biotechnology stock since 2009, according to the Form 4 filled with the SEC. Most recently James exercised 3,225 units of PDSB stock worth $9,998 on 13 June 2019.
The largest trade James's ever made was buying 50,000 units of PDS Biotechnology stock on 21 March 2016 worth over $29,500. On average, James trades about 4,319 units every 38 days since 2007. As of 13 June 2019 James still owns at least 41,861 units of PDS Biotechnology stock.
You can see the complete history of James Loughlin stock trades at the bottom of the page.
James's mailing address filed with the SEC is C/O PDS BIOTECHNOLOGY CORPORATION, 300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS, NJ, 07922.
Over the last 5 years, insiders at PDS Biotechnology have traded over $0 worth of PDS Biotechnology stock and bought 54,275 units worth $476,657 . The most active insiders traders include Gregory Gene Freitag, James J Loughlin, eKamil Ali Jackson. On average, PDS Biotechnology executives and independent directors trade stock every 67 days with the average trade being worth of $126,706. The most recent stock trade was executed by Frank Bedu Addo on 2 December 2022, trading 219,535 units of PDSB stock currently worth $1,442,345.
pds biotechnology is a clinical stage biopharmaceutical company developing the next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. pds biotechnology’s proprietary versamune® platform vector is based on synthetic and biodegradable lipids which possess a very specific structure and positive charge. the lipids form nanoparticles which activate and are taken up very efficiently by the immune system. the therapeutic product consists of versamune® formulated with a harmless form of the protein or disease-causing agent associated with the particular disease (the antigen) which our immune systems can recognize and respond to. this antigen could be a unique protein expressed only in the cancer cells and not in healthy cells, or it could be a specific viral protein(s) from an infectious virus for example. pds is in the process of completing its first phase 1 human clinical trial in 2015 for pds0101, and has initiated design and preparati
PDS Biotechnology executives and other stock owners filed with the SEC include: